<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01461720</url>
  </required_header>
  <id_info>
    <org_study_id>FF-115-2011</org_study_id>
    <nct_id>NCT01461720</nct_id>
  </id_info>
  <brief_title>Intravenous Autologous Mesenchymal Stem Cells Transplantation to Treat Middle Cerebral Artery Infarct</brief_title>
  <official_title>An Open Lable, Phase II Exploratory Study Assessing the Efficacy of Intravenous Autologous Mesenchymal Stem Cells in Patients With Middle Cerebral Artery Infarct</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University of Malaysia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cytopeutics Sdn Bhd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National University of Malaysia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine the efficacy of intravenous transplantation of autologous bone
      marrow-derived mesenchymal stem cells in patients with acute middle cerebral artery infarct.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in NIH Stroke Scale</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Barthel Index</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in modified Rankin Scale</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in size of infarct based on brain MRI stroke sequences</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Stroke Specific Quality of Life Scale</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Stroke Impact Scale</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Middle Cerebral Artery Infarction</condition>
  <arm_group>
    <arm_group_label>Standard medical care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This is the control arm, which is given the best evidence-based standard treatment for the management of acute stroke</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BM-MSCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous bone marrow-derived mesenchymal stem cells(BM-MSCs)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard medical care</intervention_name>
    <description>Standard medical care includes treatment to prevent recurrence, optimal control of risk factors and post stroke follow-up rehabilitative treatment.</description>
    <arm_group_label>Standard medical care</arm_group_label>
    <arm_group_label>BM-MSCs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous bone marrow-derived mesenchymal stem cells</intervention_name>
    <description>Single intravenous infusion of autologous bone marrow-derived mesenchymal stem cells concurrently with standard medical care.</description>
    <arm_group_label>BM-MSCs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Experiences stroke onset within 2 weeks to 2 months

          -  NIHSS score of &gt;10-35

          -  Never received or failed thrombolysis

          -  Evidence of unilateral middle cerebral artery infarct on brain MRI

        Exclusion Criteria:

          -  Medically unfit (eg. those are unstable haemodynamically despite treatment, with
             worsening conscious level and with other serious medical co-morbidity)

          -  Evidence of any tumor or other space-occupying lesion on brain MRI

          -  Evidence of hemorrhagic stroke on brain CT or MRI

          -  Experiences transient ischemic attack or lacunar infarct

          -  Has any acute or chronic infections such as Hepatitis B, Hepatitis C and HIV

          -  Is diagnosed with concurrent malignancy or primary hematological disorders

          -  Renal impairment indicated with serum creatinine greater than 200 umol/l or creatinine
             clearance less than 30 ml/min

          -  Liver impairment indicated with serum aspartate transaminase and serum alanine
             transaminase greater than 4 times upper limit of the normal range

          -  Any contraindication to stem cell transplantation or bone marrow biopsy

          -  Any co-morbidity which will compromise the ability to obtain adequate stem cells (eg.
             chronic debilitating diseases, frail patients and patients with known osteoporosis)

          -  Any contraindication to brain MRI (eg. metal implants, pacemaker, joint implants and
             ocular implants)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norlinah Mohamed Ibrahim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UKM Medical Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Norlinah Mohamed Ibrahim, MD</last_name>
    <email>norlinah@ppukm.ukm.edu.my, norlinah@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UKM Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>56000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norlinah Mohamed Ibrahim, MD</last_name>
    </contact>
    <investigator>
      <last_name>Norlinah Mohamed Ibrahim, MBBCH,MRCP,BAO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hui-Jan Tan, MRCP, MMed</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2011</study_first_submitted>
  <study_first_submitted_qc>October 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2011</study_first_posted>
  <last_update_submitted>March 30, 2015</last_update_submitted>
  <last_update_submitted_qc>March 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National University of Malaysia</investigator_affiliation>
    <investigator_full_name>Dr Norlinah Mohamed Ibrahim</investigator_full_name>
    <investigator_title>Consultant Neurologist</investigator_title>
  </responsible_party>
  <keyword>Bone marrow</keyword>
  <keyword>Autologous</keyword>
  <keyword>Mesenchymal stem cells</keyword>
  <keyword>Unilateral middle cerebral artery infarct</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Infarction, Middle Cerebral Artery</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

